AI

#AI #Biopharma #Biopharmaceuticals #Comment #DNA #Lab automation #SLAS2022 #Synthetic biology

Podcast: The impact of synthetic biology and collaboration in pharma

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save… Read More

#News

#AI #Antimicrobial resistance (AMR) #Bioscience #Drug development #Europe #Phage therapy #Research

Grant will allow development of phage therapy diagnostic platform 

Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, has received €1.8 million in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project.  The project is a phagogram using artificial intelligence (AI) that… Read More

#News

AI concept image
#AI #Drug discovery #Novel therapeutics #Pharmaceutical industry #Software

Are claims of the success of AI in drug discovery backed by science? 

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers the… Read More

#Business & Investment #Exclusive Content #Opinion

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News

Scientists look at strand of DNA on screen
#AI #Artificial intelligence (AI) #Drug development #Drug discovery #Synthetic DNA

Researchers teach AI to tailor artificial DNA for drug development

Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production.  The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at… Read More

#News

#AI #Cancer #Cancer drug targets #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

Scientists will target cancer’s ecosystems under new strategy

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded.  The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More

#Cancer Research #News

Synthetic DNA
#AI #Antibodies #Biotechnology #Drug development #Drug discovery #Synthetic biology #Synthetic DNA #Synthetic libraries

Synthetic biology tools advancing and accelerating drug discovery efforts

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery.  The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. It has made its… Read More

#Exclusive Content

Respiratory syncytial virus
#AI #Artificial intelligence (AI) #Respiratory syncytial virus #Target identification

Artificial intelligence identifies disease targets in RSV

Poolbeg Pharma and partner OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an artificial intelligence (AI) programme.  The OneThree team, using its AI platform, identified novel drug targets using Poolbeg’s RSV human challenge trial data.  The next… Read More

#News

#AI #Drug development #Drug discovery #Enzymes #Metabolomics

AI development duo to advance drug-metabolising enzymes 

Optibrium and Lhasa, developers of software and artificial intelligence (AI) solutions for drug discovery and development, have published a peer-reviewed study, Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning, where the team combined existing experimental results, quantum mechanics and machine learning to… Read More

#Business & Investment #News

Immunofluorescence
#AI #Deep learning #Immunofluorescence #Spatial biology

New tool unlocks immunofluorescence data for drug discovery

A new spatial biology platform using deep learning could establish new levels of accuracy, speed, and generalisability in multiplex immunofluorescence (mIF) analysis. While mIF is a powerful technology for cancer research, current tools for mIF image analysis are time-consuming, manual, and not robust enough to generalise across different platforms, markers… Read More

#News

The research team from the University of Illinois
#AI #Artificial intelligence (AI) #Automation / robotics #Biochemistry #Small molecules

New AI system could speed up drug discovery

A new system utilising artificial intelligence (AI), ‘building-block’ chemistry and a molecule-making machine could speed up innovation and drug discovery, as well as make complex chemistry automated and accessible. Researchers at the University of Illinois Urbana-Champaign and collaborators in Poland and Canada doubled the average yield of a special, hard-to-optimise… Read More

#News

#AI #Artificial intelligence (AI) #Brain disease #Nervous system disorders #Neuroscience #Neurotechnology

Keeping technology at the front of neuroscience research 

Listen to this article on the DDW Podcast: David Gray, CSO of Inscopix talks to Lu Rahman about the company’s understanding of the neuroscience market and its quest to improve technologies for neuroscientists to enable multimodal research.  Inscopix is a neurotechnology company focused on understanding the function of the brain to… Read More

#Exclusive Content

#AI #Deep learning #Drug discovery #Investment #Machine learning

€30 million raised to advance AI enabled drug discovery pipeline 

Aqemia has raised €30 million in a Series A funding round to further support its mission to massively scale drug discovery through a first-in-class technological platform combining quantum-inspired physics and machine learning.  The financing was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of Elaia… Read More

#Business & Investment #News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Interview #Oncology #PharmEnable

Sitting down with… PharmEnable

Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics… Read More

#Exclusive Content

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

#AI #Assay development optimisation & technology #Automation / robotics #Biotechnology #Lab automation

Automation, AI and advancing the adjacent possible

Markus Gershater, CSO and Co-Founder of Synthace discusses how technologies such as AI and automation are helping advance biotech and drug discovery.  On June 5th, 1833, Charles Babbage presented a small working part of his “Difference Engine No 1” to a group of interested onlookers. Sitting in the audience was Ada Lovelace, a… Read More

#Exclusive Content